Evidence map›Paper›PMID 30361524›Full record

ArticleBritish journal of cancer2018

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study.

Pamela Munster, Ian E Krop, Patricia LoRusso, Cynthia Ma, Barry A Siegel, Anthony F Shields, István Molnár, Thomas J Wickham, Joseph Reynolds, Karen Campbell and 5 more

Abstract readClinical Trial, Phase IComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Application of nanoparticles in breast cancer treatment: a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Nanoparticles: An Emerging Hope in Cancer Therapy.Nanomaterials (Basel, Switzerland) · 2026
    Review
  8. Review
  9. Materials today. Bio · 2025
    Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Pamela MunsterHelen Diller Family Comprehensive Cancer Center, Department of Medicine, University of California, San Francisco, CA, USA. Pmunster@medicine.ucsf.edu.
Ian E KropDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Patricia LoRussoYale Cancer Center, New Haven, CT, USA.
Cynthia MaDepartment of Medicine and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
Barry A SiegelMallinckrodt Institute of Radiology and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
Anthony F ShieldsDepartment of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
István MolnárResearch and Development, Merrimack Pharmaceuticals, Inc, Cambridge, MA, USA.
Thomas J WickhamResearch and Development, Merrimack Pharmaceuticals, Inc, Cambridge, MA, USA.
Joseph ReynoldsResearch and Development, Merrimack Pharmaceuticals, Inc, Cambridge, MA, USA.
Karen CampbellResearch and Development, Merrimack Pharmaceuticals, Inc, Cambridge, MA, USA.
Bart S HendriksResearch and Development, Merrimack Pharmaceuticals, Inc, Cambridge, MA, USA.
Bambang S AdiwijayaResearch and Development, Merrimack Pharmaceuticals, Inc, Cambridge, MA, USA.
Elena GerettiResearch and Development, Merrimack Pharmaceuticals, Inc, Cambridge, MA, USA.
Victor MoyoResearch and Development, Merrimack Pharmaceuticals, Inc, Cambridge, MA, USA.
Kathy D MillerIndiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA.

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI David G DeNardo · 2001 to 2026
$128.0M
NCI NIH HHS P30 CA091842
6 · The paper itself

Abstract

backgroundThis phase 1 dose-escalation trial studied MM-302, a novel HER2-targeted PEGylated antibody-liposomal doxorubicin conjugate, in HER2-positive locally advanced/metastatic breast cancer.

methodsPatients were enrolled in four cohorts: MM-302 monotherapy (8, 16, 30, 40, and 50 mg/m

resultsSixty-nine patients were treated. The most common adverse events (AEs) were fatigue and nausea. Grade 3/4 AEs of special interest included neutropenia, fatigue, mucosal inflammation, anemia, thrombocytopenia, febrile neutropenia, and palmar-plantar erythrodysesthesia. The MTD was not reached. With MM-302 ≥ 30 mg/m

conclusionMM-302 monotherapy, in combination with trastuzumab, or trastuzumab plus cyclophosphamide, was well tolerated and showed promising efficacy. The selected phase 2 MM-302 dose was 30 mg/m

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBrainBreast NeoplasmsCyclophosphamideDose-Response Relationship, DrugDoxorubicinDrug Administration ScheduleErb-b2 Receptor Tyrosine KinasesFemaleHumansImmunoconjugatesSingle-Chain AntibodiesSurvival AnalysisTrastuzumabCyclophosphamideDoxorubicinERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesgancotamabImmunoconjugatesSingle-Chain AntibodiesTrastuzumab

Identifiers

PMID30361524
PMCPMC6219487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.